Latest MedImmune Stories
RALEIGH, North Carolina and QUEBEC CITY, Quebec, Nov. 10, 2011 /PRNewswire/ - Medicago U.S.A. Inc., a wholly owned subsidiary of Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that company executives, along with North Carolina Governor Beverly Perdue, U.S. Senator Richard Burr and Congressman David Price, are holding an...
COPENHAGEN, Denmark and SEATTLE, Nov. 9, 2011 /PRNewswire/ -- Single-use technologies are widely accepted in the biomanufacturing of biological therapeutics and vaccines. Pharma/biopharmaceutical companies, contract manufacturing organizations, engineering firms, and leading technology suppliers are embracing advances in disposable technologies. Over 120 delegates from the biomanufacturing industry attended a two-day 'Single-Use Technology Seminar' in Copenhagen on 25-26th October. The...
GAITHERSBURG, Md., Nov. 8, 2011 /PRNewswire/ -- MedImmune, the global biologics arm of AstraZeneca, today announced that the company's expansion project at its Frederick, Md., Manufacturing Center (FMC) won the International Society for Pharmaceutical Engineering's overall 2011 Facility of the Year Award. This is the first time MedImmune has won this prestigious internationally renowned accolade. The annual Facility of the Year Awards (FOYA), sponsored by the ISPE, INTERPHEX and...
PORTLAND, Ore., Oct. 31, 2011 /PRNewswire/ -- AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer. "We are very pleased to collaborate with MedImmune to advance our OX40 agonist programs," said AgonOx CEO Llew...
BOSTON, Oct. 26, 2011 /PRNewswire/ -- 13 leading industry speakers will present at CBI's 2nd Annual Pharma/Bio Boot Camp on Electronic Trial Master Files on November 14-15, 2011 in Philadelphia. Nearly 100 TMF professionals convene for this interactive and educational exploration of the major shift taking place in the clinical trials -- moving from paper documentation to electronic files. Often called the heart of a clinical trial, the TMF is re-examined as it moves to a more effective and...
People carrying extra pounds may need extra protection from influenza. New research from the University of North Carolina at Chapel Hill shows that obesity may make annual flu shots less effective. The findings, published online Oct. 25, 2011, in the International Journal of Obesity, provide evidence explaining a phenomenon that was noticed for the first time during the 2009 H1N1 flu outbreak: that obesity is associated with an impaired immune response to the influenza vaccination in...
BOSTON, Oct. 21, 2011 /PRNewswire/ -- MedImmune announced today it will present results of a Phase 3 pediatric clinical study of its investigational quadrivalent live attenuated influenza vaccine (Q/LAIV) compared with its trivalent (LAIV) formulation. The abstract will be presented at the 49th Annual Meeting of Infectious Disease Society of America (IDSA) being held here October 20 through October 23, 2011. The pivotal pediatric clinical study compared Q/LAIV to two...
ST. PAUL, Minn., Oct. 20, 2011 /PRNewswire/ -- Children given an injectable medication to help prevent severe respiratory illness had a 17.6 percent higher likelihood of receiving the American Academy of Pediatrics (AAP) recommended doses when they were administered through a specialty pharmacy rather than a traditional pharmacy, according to a new study released today by pharmacy benefit manager Prime Therapeutics (Prime). The study will be presented today at the Academy of Managed Care...
GAITHERSBURG, Md., Oct. 13, 2011 /PRNewswire/ -- Families are busy enough during the back-to-school season - new class schedules, countless extracurricular activities, and daily homework assignments - without having to worry about the flu. To help raise awareness about the importance of annual influenza vaccination as the recommended best defense against the disease, MedImmune, along with soccer legend and mom Brandi Chastain, today launched the second year of "When Will You Pick?," a...
A novel dry-powder formulation nasal flu vaccine for the H5N1 strain, GelVacâ„¢ Nasal Dry-Powder H5N1 Influenza, was proven to be safe in an early stage clinical trial. Other preliminary data is encouraging and support the development of larger scale clinical trials to confirm efficacy and show its distinct advantages in meeting the critical needs of pandemic preparedness. Alachua, Florida (PRWEB) October 03, 2011 Nanotherapeutics, Inc. announced the successful completion of a Phase 1...
